The oncometabolite 2-hydroxyglutarate is markedly elevated in ERα-negative human breast tumors of the basal-like/mesenchymal subtype and this has been linked to poor clinical outcome, c-Myc activation, and glutamine dependence42. Here, ESR1 is linked to breast neoplasm.